Un premier anticorps multispécifique engageant les cellules NK d'Innate sélectionné par Sanofi comme candidat-médicament
05 janv. 2021 01h00 HE
|
INNATE PHARMA
Marseille, 05 janv. 2021 (GLOBE NEWSWIRE) -- IPH6101/SAR443579 est un anticorps multispécifique engageant les cellules NK (NKCE) via leur récepteur activateur NKp46 et utilisant le format...
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
24 oct. 2020 09h45 HE
|
Revolution Medicines, Inc.
Plenary Presentation at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profiles for RMC-4630 Combined with Cobimetinib and...
BioNTech to Present Data from BNT311 (GEN1046) and BNT131 (SAR441000) Programs at SITC 35th Annual Meeting
14 oct. 2020 17h00 HE
|
BioNTech SE
Data updates from key oncology collaborations to be presentedPreliminary data from the first-in-human trial from intratumoral immunotherapy program BNT131 (SAR441000) in collaboration with Sanofi, to...
Global Systemic Lupus Erythematosus Market – Estimated to Gain Traction with Arrival of Key Pipeline Agents, with Promising Higher Efficacy than Existent Therapies - PMI
20 août 2020 10h35 HE
|
PMI
Covina, CA, Aug. 20, 2020 (GLOBE NEWSWIRE) -- The report "Global Systemic Lupus Erythematosus Market, By Drug Classes (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, and Biologics),...
Global Neurodegenerative Disorder Therapeutics Market - Improvement in the healthcare infrastructure is likely to create new opportunity for the market
13 août 2020 10h34 HE
|
PMI
Covina, CA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- The report "Global Neurodegenerative Disorder Therapeutics Market, By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis,...
Translate Bio Announces Closing of Expanded Collaboration and Licensing Agreement with Sanofi Pasteur to Develop mRNA Vaccines for All Infectious Diseases
20 juil. 2020 16h05 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Sanofi and Translate Bio Expand Collaboration to Develop mRNA Vaccines Across All Infectious Disease Areas
23 juin 2020 00h59 HE
|
Translate Bio, Inc.
-- The two companies will build upon their existing collaboration to pursue novel mRNA vaccines aimed at broadly addressing current and future infectious diseases -- -- Translate Bio to receive...
Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor
22 juin 2020 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier...
Le Conseil d’administration de Sanofi prend acte de la démission d’Emmanuel Babeau et coopte Gilles Schnepp en tant qu’administrateur indépendant
28 mai 2020 12h05 HE
|
Sanofi
Prend acte de la démission d’Emmanuel Babeau avec effet au 22 mai 2020Coopte Gilles Schnepp pour la durée du mandat restant à courir d’Emmanuel Babeau PARIS – Le 28 mai 2020 – Le Conseil...
Sanofi’s Board of Directors notes the resignation of Emmanuel Babeau and coopts Gilles Schnepp as Independent Director
28 mai 2020 12h05 HE
|
Sanofi
Notes the resignation of Emmanuel Babeau as of May 22, 2020Coopts Gilles Schnepp for the remainder of Emmanuel Babeau’s term of office PARIS – May 22, 2020 – At its meeting held on May 22, 2020, the...